Kashmiri
Rafia Mehdi Kashmiri, North Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20080274055 | Framework Residue Substituted Humanized Col-1 Antibodies and Their Use - The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein. | 11-06-2008 |
20110053264 | FRAMEWORK RESIDUE SUBSTITUTED HUMANIZED COL-1 ANTIBODIES AND THEIR USE - The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein. | 03-03-2011 |
Sayyed Mahdi Kashmiri, Delft NL
Patent application number | Description | Published |
---|---|---|
20110187428 | Electrothermal frequency reference - An electrothermal frequency-locked loop (EFLL) circuit is described. This EFLL circuit includes an oscillator in a feedback loop. A drive circuit in the EFLL circuit generates a first signal having a fundamental frequency, and an electrothermal filter (ETF) in the EFLL circuit provides a second signal based on the first signal. This second signal has the fundamental frequency and a phase (relative to the first signal) that corresponds to a temperature-dependent time constant of the ETF. Moreover, a sensing component in the EFLL circuit determines a parameter associated with a temperature of the ETF. For example, the parameter may be the temperature or may be other than the temperature, such as the fundamental frequency and/or the phase of the second signal. Furthermore, the EFLL circuit includes a compensation circuit that compensates for frequency changes associated with changes in the temperature based at least on the parameter so that the fundamental frequency is approximately independent of the temperature. | 08-04-2011 |
20140285189 | FLUXGATE MAGNETIC-TO-DIGITAL CONVERTER WITH OVERSAMPLING CLOSED LOOP - A fluxgate sensor including a magnetic-to-digital converter (MDC) can be adapted to measure an external magnetic field B | 09-25-2014 |
Syed Kashmiri, North Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20080274055 | Framework Residue Substituted Humanized Col-1 Antibodies and Their Use - The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein. | 11-06-2008 |
20110053264 | FRAMEWORK RESIDUE SUBSTITUTED HUMANIZED COL-1 ANTIBODIES AND THEIR USE - The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein. | 03-03-2011 |
Syed V.s. Kashmiri, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20090311780 | MINIMALLY IMMUNOGENIC VARIANTS OF SDR-GRAFTED HUMANIZED ANTIBODY CC49 AND THEIR USE - Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28′ CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72. | 12-17-2009 |
20090317903 | HUMANIZED ANTI-TAG 72 CC49 FOR DIAGNOSIS AND THERAPY OF HUMAN TUMORS - The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein. | 12-24-2009 |
20100303720 | VARIANTS OF HUMANIZED ANTI-CARCINOMA MAb CC49 - The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining | 12-02-2010 |
Syed V.s. Kashmiri, Gaithersberg, MD US
Patent application number | Description | Published |
---|---|---|
20110159525 | METHODS TO DETERMINE IMMUNOGENICITY OF HUMANIZED ANTI-TAG 72 CC49 ANTIBODIES - The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody. | 06-30-2011 |
Syed V.s. Kashmiri, North Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20130337559 | HUMANIZED ANTI-TAG 72 CC49 FOR DIAGNOSIS AND THERAPY OF HUMAN TUMORS - The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody. | 12-19-2013 |